Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
NCT ID: NCT02702323
Last Updated: 2016-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
40 participants
INTERVENTIONAL
2016-03-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
NCT02727309
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
NCT03066557
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
NCT03510416
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
NCT05550025
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
NCT02772029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Apatinib & TACE
Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
Apatinib
apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
TACE
one times every 4-6 weeks.
TACE
TACE therapy one times every 4-6 weeks.
TACE
one times every 4-6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apatinib
apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
TACE
one times every 4-6 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* refused to sorafenib treatment
* have at least one measurable pulmonary lesions
* expected survival time ≥ 12 weeks
Exclusion Criteria
* With a variety of factors influencing oral drugs taking and absorption (such as unable to swallow, chronic diarrhea and intestinal obstruction)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
The Central Hospital of Lishui City
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Ningbo No.2 Hospital
OTHER
Zhejiang Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
guoliang shao
Vice President
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
guoliang shao, phD
Role: STUDY_CHAIR
Zhejiang Cancer Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ahead-H302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.